KIR2DL4 and neoplasm: Antibodies against HLA-G/KIR2DL4 combined with trastuzumab and NK cells, but not blocking antibodies alone, suppressed tumor growth in vivo, suggesting that these blocking antibodies exert a tumoricidal role at least partially by enhancing ADCC activity (Supplementary Fig. S13).